Status:
COMPLETED
Atherosclerosis in Rheumatoid Arthritis and Lupus: Restoring Cholesterol Balance
Lead Sponsor:
NYU Langone Health
Collaborating Sponsors:
Arthritis Foundation
Conditions:
Rheumatoid Arthritis
Eligibility:
All Genders
18-65 years
Brief Summary
Hypothesis: SLE and RA increase risk of myocardial infarction (MI, heart attack). Immune reactants in the circulation of SLE patients downregulate cholesterol efflux proteins 27-hydroxylase and ABCA1 ...
Detailed Description
Atherosclerotic cardiovascular disease (ASCVD) is a major cause of morbidity and mortality, especially in patients with autoimmune disorders such as systemic lupus erythematosus (lupus) and rheumatoid...
Eligibility Criteria
Inclusion
- Males and females age 18-65
Exclusion
- No methotrexate or statin therapy in prior 3 months.
- Not on biological therapies.
Key Trial Info
Start Date :
September 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 20 2025
Estimated Enrollment :
176 Patients enrolled
Trial Details
Trial ID
NCT01180361
Start Date
September 1 2008
End Date
June 20 2025
Last Update
October 30 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
NYU Langone Hospital - Long Island
Mineola, New York, United States, 11501